In grow-finish swine feed milling, the native Wuwei Zhenqi Powder is first screened through a 425 µm stainless-steel sieve and pre-blended with 1.0% w/w fumed silica before entering the main ribbon mixer. The pre-blend is diluted sequentially: a 5.0–15.0 wt% intermediate premix is prepared on a 500 kg double-ribbon blender at 18–22 rpm for 12–15 min, and the resulting premix is then metered into complete feed at 0.25–1.5 kg per metric ton depending on the total polysaccharide assay of the incoming lot and the veterinary health protocol in place. Uniformity of the active fraction is verified by near-infrared spectroscopy against a wet chemistry reference curve, with a coefficient of variation target of ≤5.0% across 10 sampling points; if the CV exceeds 5.0%, the blender time is extended by 5 min increments and the discharge baffle is inspected for dead zones. Medicated feed compliance for this downstream form rests on 21 CFR Part 225 and 21 CFR Part 226 for Type A medicated articles and Type B medicated feeds in the United States, while European shipments are governed by Regulation (EU) 2019/4 on medicated feed and feed intermediates; batch release records must demonstrate active component identity, moisture content, and homogeneity before the premix leaves the mill. Downstream pelleting is performed with steam conditioning at 75–80 °C under 0.25–0.35 MPa for 45–60 s, followed by a pellet die with a compression ratio of 1:8 and post-pellet cooling to ≤11.5% moisture; temperatures above 85 °C during conditioning or extended residence times in the conditioner create a measurable reduction in water-soluble polysaccharide content and should be avoided. The powder should not be pre-blended with liquid choline chloride above 0.5% w/w in the same carrier because free water release from choline chloride causes localized caking and hydrolysis; if choline chloride is required, it is applied post-pelleting via a separate metered line. Terminal finished product types include licensed medicated premix packs and pelleted complete feed for grow-finish swine, with printed label claims tied to the approved premix monograph and mill license number.

What Limits Cold-Water Dispersion of Herbal API in Poultry Drinking-Water Solubles?

The formulation bottleneck in poultry drinking-water delivery is not active assay but hydration time in cold water and re-dispersibility after line pause. For Wuwei Zhenqi Powder, dry blending alone produces stratification and slow settling in water at 8–12 °C; therefore fluid-bed top-spray granulation is used to convert the native powder and its carrier into a low-dust granule with a particle size D50 of 180–350 µm. The native powder is loaded at 10.0–25.0 wt% of the granulated drinking-water formulation, with the balance composed of spray-dried lactose, maltodextrin, and 0.2–0.5 wt% colloidal silicon dioxide; the blend is sprayed with a 2.0% w/w povidone K30 aqueous binder solution at an inlet air temperature of 55–65 °C, product temperature of 32–38 °C, and spray rate of 80–120 g/min. Residual moisture is controlled to ≤3.0% before discharge, because higher moisture accelerates polysaccharide degradation and impairs flow into high-speed sachet fillers. Finished granules are packed into triple-laminate foil pouches with 3 g silica desiccant to maintain a headspace relative humidity below 30% over the shelf life. Regulatory alignment for this drinking-water soluble powder is established under Regulation (EU) 2019/6 for veterinary medicinal products where a marketing authorisation is required, and under 21 CFR Part 210/211 current good manufacturing practice for finished pharmaceuticals when the product is registered as a Type A medicated article; residual solvent control follows VICH GL18, and dissolution testing is conducted in water at 10 °C and 20 °C to demonstrate that the granule wets within 60 s and passes a 180 µm wet sieve. Field use is typically 0.5–2.0 g/L in drinking water over 5–7 days, but the line must be flushed after each dosing period because polysaccharide residue can support biofilm growth; free chlorine at ≥0.2 ppm in the dilution water oxidizes exposed polysaccharide chains and reduces assay, so baseline water quality must be recorded before batch release. Terminal finished product types include water-soluble granular packs, water-dispersible powder sachets, and pre-measured drinking-water dosing vials for poultry houses integrated with proportioner medicators.Roller compaction is selected over direct compression for ruminant oral tablets and large boluses because the native Wuwei Zhenqi Powder has poor flow properties and a tendency to adhere to high-speed tableting tooling at ambient humidity. The active powder is first dried at 50 °C in a vacuum tray dryer to a loss-on-drying specification of ≤3.0% and then milled through a 0.8 mm screen; magnesium stearate is withheld until the final lubrication step. A pilot-scale roller compactor with roll pressure of 45–65 bar compacts the blend into ribbons that are granulated through a 1.0 mm oscillator. The core tablet contains 20.0–35.0 wt% native powder, 25.0–40.0 wt% microcrystalline cellulose, 2.0–4.0 wt% croscarmellose sodium, and 0.5 wt% magnesium stearate. Compression is carried out on a rotary tablet press at 40,000–80,000 tablets/h with main compression force of 8–16 kN; hardness is maintained at 70–120 N and friability at ≤1.0% as measured by USP <1216>. Disintegration is tested in 0.1 N HCl at 37 ± 2 °C, with a limit of ≤30 min for boluses and ≤15 min for smaller tablets. Compliance for this dosage form is anchored to 21 CFR Part 211 for finished veterinary pharmaceuticals, USP <905> for uniformity of dosage units, and USP <701> for disintegration; process validation batches must include moisture, hardness, thickness, and assay testing at beginning, middle, and end of the compression run. Wet granulation with water is not recommended because the polysaccharide fraction becomes tacky above 10% moisture and can adhere to dryer walls; if granulation is unavoidable, a non-aqueous binder system or dry binder addition is used. Terminal finished product types include short-duration oral tablets, sustained-release rumen boluses with a density of 2.0–2.6 g/cm³, and split-dose scored tablets for cattle and small ruminants.

Aquaculture Top-Dress Powders and Low-Temperature Extrusion Granules

Low-temperature post-extrusion coating is the standard insertion point for heat-sensitive herbal powders in aquaculture feeds because high-shear extrusion above 85 °C can reduce total polysaccharide content and alter the powder’s dispersibility in the gut. Wuwei Zhenqi Powder is applied as a vacuum-coated top-dress or as a low-temperature extrusion granule at 1.0–3.0 kg per metric ton of finished feed for the top-dress route, or 0.05–0.5 wt% of the extruded pellet if incorporated before low-temperature pelleting. The vacuum coating process uses a horizontal vacuum coater operated at -0.06 to -0.08 MPa for 8–10 min; fish oil or vegetable oil binder is sprayed at 2.0–4.0% w/w during the first phase, followed by the active powder blend and a second oil phase to seal the surface. Pellet moisture after coating is reduced to ≤10.0% by dry air at 50 °C, and the coated pellets are sieved through a 2.0 mm screen to remove agglomerates. Compliance for aquaculture feeds is governed by 21 CFR Part 225 and 21 CFR Part 226 where medicated feed is imported into the United States, by Regulation (EU) 2019/4 and associated Hazard Analysis and Critical Control Point systems under ISO 22000 for feed safety in the European system, and by residue control programmes aligned with Codex maximum residue limits for aquaculture products where applicable. The powder should not be directly extruded through a single-screw extruder with barrel temperatures above 95 °C; published data for this specific configuration is limited, so thermal degradation studies on the marker compound should be generated for each formulation before commercial scale-up. Terminal finished product types include vacuum-coated floating pellets, sinking pellets with top-dress powder, and on-farm premix packs for shrimp and freshwater fish.

When Aseptic Filtration Replaces Terminal Heat Sterilization in Injectable Presentations

Aseptic processing of Wuwei Zhenqi Powder injectable solutions requires a two-stage filtration train because terminal steam sterilisation at 121 °C for 15 min causes hydrolysis of water-soluble polysaccharides and generates visible subvisible particulate growth within 24 h. The powder is dissolved in Water for Injection at 25–35 °C with continuous impeller agitation for 60–90 min; the pH is adjusted to 6.5–7.2 with 0.1 M sodium hydroxide or hydrochloric acid, and tonicity is adjusted with 0.9% w/v sodium chloride or an alternative isotonic diluent validated for the species. The native powder is loaded at 0.05–0.5% w/v based on dry solids, equivalent to a polysaccharide concentration commonly in the range of 0.1–1.0 mg/mL depending on assay. The solution is prefiltered through a 0.45 µm polypropylene depth filter, then sterilized through a 0.22 µm PVDF membrane filter; the filtration train is integrity tested by bubble point or forward flow before and after use. Filling is performed in an ISO 14644-1 Class 7 background with an EU GMP Grade A unidirectional airflow zone, using 10 mL amber glass vials under nitrogen headspace to reduce oxidative degradation. Compliance is anchored to 21 CFR 211.113 for microbiological control, 21 CFR 211.167 for sterility and pyrogen testing, USP <71> for sterility tests, USP <85> for bacterial endotoxins, and VICH GL18 for residual solvents from extraction and purification. Endotoxin control is critical: if the bulk solution exceeds 0.5 EU/mL, a 10 kDa ultrafiltration step is inserted before the final filter, but this can reduce yield and must be validated. Terminal finished product types include sterile injectable solutions for intravenous, intramuscular, or subcutaneous administration in food-producing and companion animals, in sealed amber vials with tamper-evident caps.

Companion Animal Capsule Fill Direct Compression Grade Properties

Direct-filled hard gelatin capsules containing the native powder are manufactured under low-humidity conditions because the polysaccharide fraction absorbs moisture from the air and can soften the capsule shell. The capsule blend contains 10.0–25.0 wt% Wuwei Zhenqi Powder, 60.0–75.0 wt% spray-dried lactose or microcrystalline cellulose, 0.5 wt% colloidal silicon dioxide, and 0.5–1.0 wt% magnesium stearate; the blend is mixed in a bin blender at 25 rpm for 20 min and then discharged into a capsule filler operating at 60,000–100,000 capsules/h. Fill weight is controlled to 300–500 mg per capsule, with the active powder dose delivered at 50–150 mg per capsule depending on the species and body weight; empty shell size is size 0 or size 1, and the filled capsules are mechanically sorted through a weight checkweigher with a rejection limit of ±3.0% of target fill weight. Compliance for this downstream form is established under 21 CFR Part 211 for finished veterinary pharmaceuticals, USP <905> for uniformity of dosage units, USP <701> for disintegration, and USP <2091> for weight variation of nutritional supplements where applicable; residual moisture of the filled capsule is controlled to ≤3.5%. The powder should not be combined with hygroscopic carriers such as sorbitol above 3.0% w/w, because moisture transfer from the fill to the capsule shell produces brittle fracture at the cap-body joint within 6 months of storage. Published comparative dissolution data for Wuwei Zhenqi Powder in feline and canine gastric fluid is limited; therefore release limits must be justified using pilot batch dissolution profiles in 0.1 N HCl and biorelevant media before scale-up. Terminal finished product types include two-piece hard gelatin capsules in blister packaging, vegan hypromellose capsule variants where required by the market, and bulk capsule bottles for veterinary dispensing.

Table 1. Compliance matrix for Wuwei Zhenqi Powder downstream finished forms

Finished form	Primary compliance reference	Critical process verification	Release test standard
Swine medicated premix	21 CFR Part 225, 21 CFR Part 226, Regulation (EU) 2019/4	Ribbon blender uniformity, premix carryover	NIR assay vs wet chemistry, moisture ≤11.5%
Poultry water-soluble granule	Regulation (EU) 2019/6, 21 CFR Part 210/211	Granule particle size D50, wetting time	HPLC marker assay, LOD ≤3.0%
Ruminant tablet or bolus	21 CFR Part 211, USP <905>	Compression force, friability	Hardness 70–120 N, disintegration ≤30 min
Aquaculture coated pellet	21 CFR Part 225, ISO 22000, Regulation (EU) 2019/4	Vacuum coating uniformity, moisture	Marker assay, moisture ≤10.0%
Injectable solution	21 CFR 211.113, USP <71>, USP <85>	Filter integrity test, bioburden pre-filtration	Sterility, endotoxin ≤0.5 EU/mL
Companion animal capsule	21 CFR Part 211, USP <905>	Fill weight, moisture transfer	Weight variation ±3.0%, LOD ≤3.5%

Table 2. Representative formulation gradients for Wuwei Zhenqi Powder at production scale

Target species and form	Native powder loading	Carrier or diluent system	Critical moisture limit	Primary incompatibility
Swine premix	5.0–15.0 wt% intermediate; 0.25–1.5 kg/t complete feed	Fumed silica, ground corn cob or calcium carbonate	≤11.5% post-pelleting	liquid choline chloride above 0.5% w/w
Poultry drinking-water granule	10.0–25.0 wt%	Spray-dried lactose, maltodextrin	≤3.0% after granulation	free chlorine ≥0.2 ppm in dilution water
Ruminant tablet	20.0–35.0 wt%	Microcrystalline cellulose, croscarmellose sodium	≤3.0% before compression	wet granulation above 10% moisture
Aquaculture coated pellet	0.05–0.5 wt% incorporated; 1.0–3.0 kg/t top-dress	Fish oil or vegetable oil binder	≤10.0% final pellet	extrusion above 85 °C
Injectable solution	0.05–0.5% w/v dry solids	Water for Injection, sodium chloride or isotonic diluent	low moisture not applicable	terminal steam sterilization at 121 °C
Companion animal capsule	10.0–25.0 wt%	Spray-dried lactose, microcrystalline cellulose	≤3.5% filled capsule	hygroscopic sorbitol above 3.0% w/w